Aditum Bio launches third company, Anteris Bio, in collaboration with TrialSpark

Aditum Bio launches third company, Anteris Bio, in collaboration with TrialSpark
- Aditum Bio "spin-out" companies such as Anteris Bio will leverage TrialSpark's clinical development engine to rapidly advance their drug assets through clinical trials.
News provided by
Share this article
Share this article
NEW YORK, Dec. 16, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, formally announces a collaboration with Aditum Bio, a San Francisco-based venture firm focused on acquiring and developing biotechnology assets that will benefit patients.
Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug development partner, TrialSpark will support Anteris Bio using its innovative, tech-enabled clinical development model.

Related Keywords

Anteris Bio ,Michael Moritz ,Mark Fishman ,John Doerr ,Ben Liu ,Joe Jimenez ,Tempero Bio ,Aditum Bio ,Sequoia Capital ,Novartis ,San Francisco Based ,Managing Director ,Chief Executive Officer ,Thrive Capital ,மைக்கேல் மோரிட்ஸ் ,குறி மீன் ,ஜான் தோேறுற் ,பென் லியூ ,ஓஹோ ஜிமெனெஸ் ,சீக்வோயா மூலதனம் ,நோவர்த்திச் ,சான் பிரான்சிஸ்கோ அடிப்படையிலானது ,நிர்வகித்தல் இயக்குனர் ,தலைமை நிர்வாகி அதிகாரி ,செழித்து வளருங்கள் மூலதனம் ,